A5016025995- Ultrasound and Hyperthermia Applications
- Glioma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Nanoplatforms for cancer theranostics
- Electron Spin Resonance Studies
- Mathematical Biology Tumor Growth
- Lanthanide and Transition Metal Complexes
- Ferroptosis and cancer prognosis
- Medical Imaging Techniques and Applications
- Brain Metastases and Treatment
- Photoacoustic and Ultrasonic Imaging
- Advanced MRI Techniques and Applications
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2023-2024
Northwestern University
2023-2024
Neurological Surgery
2023-2024
Northwestern Medicine
2023-2024
Abstract Purpose: We recently reported on clinical trials for patients with recurrent glioblastoma where low-intensity pulsed ultrasound and microbubbles (LIPU/MB) improved paclitaxel or carboplatin delivery into the brain. Here, we report variable local tumor control at maximal/target dose in our phase I trial (NCT04528680). To address this, investigated combination of preclinical glioma models. Experimental Design: performed MRI-based analysis to evaluate disease from trial. studied...
<p>Supplementary Figure 3. Association of p-ERK with survival in glioblastoma patients treated immune checkpoint blockade.</p>
<p>Supplementary Figure 3. Association of p-ERK with survival in glioblastoma patients treated immune checkpoint blockade.</p>
<div>AbstractPurpose:<p>Evidence suggests that MAPK pathway activation, as measured by ERK1/2 phosphorylation (p-ERK), predicts overall survival (OS) in patients with recurrent glioblastoma receiving anti-PD-1 therapy. We aimed to validate these findings independent cohorts.</p>Experimental Design:<p>In a 24-patient clinical trial on and high-grade gliomas, we examined the link between p-ERK levels OS. Patients received intravenous nivolumab, followed maximal safe...
<div>AbstractPurpose:<p>Evidence suggests that MAPK pathway activation, as measured by ERK1/2 phosphorylation (p-ERK), predicts overall survival (OS) in patients with recurrent glioblastoma receiving anti-PD-1 therapy. We aimed to validate these findings independent cohorts.</p>Experimental Design:<p>In a 24-patient clinical trial on and high-grade gliomas, we examined the link between p-ERK levels OS. Patients received intravenous nivolumab, followed maximal safe...
<p>Supplementary Figure 2. Survival outcomes of high-grade gliomas in evaluable patients</p>
<p>Supplementary Figure 1. Workflow employed for software-assisted quantification of immunohistochemistry through the marking p-ERK+ cells.</p>
<p>Supplementary Figure 2. Survival outcomes of high-grade gliomas in evaluable patients</p>
<p>Supplementary Figure 1. Workflow employed for software-assisted quantification of immunohistochemistry through the marking p-ERK+ cells.</p>
<p>Supplementary Material and Methods</p>
<p>Supplementary Figure 4. Paclitaxel and carboplatin combination lead to cell cycle arrest in the S G2/M phases. Results of flow cytometric analysis synchronized GBM6 MES83 cells that received PTX, CBDCA, or a both drugs for 24 48 hours. On right, we show proportion arrested at each SubG1, G0/G1, S, phases.</p>
<div>AbstractPurpose:<p>We recently reported on clinical trials for patients with recurrent glioblastoma where low-intensity pulsed ultrasound and microbubbles (LIPU/MB) improved paclitaxel or carboplatin delivery into the brain. Here, we report variable local tumor control at maximal/target dose in our phase I trial (NCT04528680). To address this, investigated combination of preclinical glioma models.</p>Experimental Design:<p>We performed MRI-based analysis to...
<p>Supplementary Figure 1. Paclitaxel delivered with low-intensity pulsed ultrasound and microbubbles leads to variable local tumor control. Coronal T1 contrast MRI images of patients from our phase I clinical trial (NCT04528680) who received the highest dose Abraxane (260 mg/m2). We illustrate in green area covered by sonication, observe a control within this region. The five presented upper (blue) panel exhibited control, while remaining (in red) had growth on therapy.</p>
<div>AbstractPurpose:<p>We recently reported on clinical trials for patients with recurrent glioblastoma where low-intensity pulsed ultrasound and microbubbles (LIPU/MB) improved paclitaxel or carboplatin delivery into the brain. Here, we report variable local tumor control at maximal/target dose in our phase I trial (NCT04528680). To address this, investigated combination of preclinical glioma models.</p>Experimental Design:<p>We performed MRI-based analysis to...
<p>Supplementary Figure 2. Human glioma cell lines exhibit variable responses to paclitaxel and carboplatin. (A) Dose-response curves showing the response PTX (blue) CBDCA (red) in human lines. (B) Bar chart maximal efficacy (Emax) of against </p>
<p>Supplementary Figure 3. Paclitaxel and carboplatin exhibit synergy in vitro. (A) Dose-response matrices illustrating the Loewe score calculated for 11 glioma cell lines at clinically relevant PTX CBDCA concentrations. (B) Bar charts showing viability of treated with PTX, CBDCA, or a combination both drugs concentration that showed highest synergy.</p>
<p>Supplementary Figure 3. Paclitaxel and carboplatin exhibit synergy in vitro. (A) Dose-response matrices illustrating the Loewe score calculated for 11 glioma cell lines at clinically relevant PTX CBDCA concentrations. (B) Bar charts showing viability of treated with PTX, CBDCA, or a combination both drugs concentration that showed highest synergy.</p>
<p>Supplementary Figure 1. Paclitaxel delivered with low-intensity pulsed ultrasound and microbubbles leads to variable local tumor control. Coronal T1 contrast MRI images of patients from our phase I clinical trial (NCT04528680) who received the highest dose Abraxane (260 mg/m2). We illustrate in green area covered by sonication, observe a control within this region. The five presented upper (blue) panel exhibited control, while remaining (in red) had growth on therapy.</p>
<p>Supplementary Figure 4. Paclitaxel and carboplatin combination lead to cell cycle arrest in the S G2/M phases. Results of flow cytometric analysis synchronized GBM6 MES83 cells that received PTX, CBDCA, or a both drugs for 24 48 hours. On right, we show proportion arrested at each SubG1, G0/G1, S, phases.</p>